Studies of Neuregulin/ERBB Signaling in Human Heart

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-06-30

Study Completion Date

2029-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study examines the role of the epidermal growth factor (EGF) receptor family and the EGF family of ligands in the regulation of non-myocytes isolated from the human heart.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Endothelial Progenitor Cells and Nitric Oxide in Cardiac Rehabilitation Program Participants

NCT00308633

Coronary Artery Disease (CAD)

COMPLETED

Prospective Becker-Heart-Study

NCT02020954

Dilated Cardiomyopathy Lef Ventricular Dysfunction Heart Failure

UNKNOWN

Mobile Health in Structural Heart Disease

NCT02881398

Rheumatic Heart Disease Heart Diseases

COMPLETED PHASE2/PHASE3

Leveraging Exercise Stress Echocardiography for Heart Failure With Preserved Ejection Fraction

NCT06927973

Chest Pain Shortness of Breath

COMPLETED NA

Circulating Markers for Ischemic Heart Disease

NCT00762333

Myocardial Infarction Ischemia Congestive Heart Failure

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The EGF family of receptor tyrosine kinases (a.k.a. ERBB receptors) mediate the effects of the epidermal growth factor (EGF) family including Neuregulin-1β (NRG). NRG and ERBB1-4 are critical for cardiac development and maintenance of the adult heart. Current understanding of the role of EGF/NRG/ERBB signaling in the cardiovascular system is rapidly evolving due to recent findings in non-myocyte cell populations. This study is examining a population of progenitor cells in the adult human heart that responds to EGF and NRG. Subjects are enrolled who are scheduled to undergo heart surgery and are willing to allow for a small biopsy to be taken from their hearts during surgery. Biopsies are taken to the laboratory where cells are separated and analyzed by flow cytometry and grown in cell culture to understand how their biology is regulated by NRG and EGF.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Disease Vascular Disease Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of severe coronary artery disease scheduled to undergo coronary artery bypass surgery.

Exclusion Criteria

* less than 18 years of age
* unwilling or unable to provide informed consent
* known active myocarditis
* hypertrophic cardiomyopathy
* constrictive pericarditis or other significant pericardial disease
* severe pulmonary hypertension
* significant renal impairment (Cr \> 2.5 mg/dL)
* severe ventricular arrhythmias
* pregnancy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No